228 related articles for article (PubMed ID: 27030813)
1. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients.
Rutten IJ; van Dijk DP; Kruitwagen RF; Beets-Tan RG; Olde Damink SW; van Gorp T
J Cachexia Sarcopenia Muscle; 2016 Sep; 7(4):458-66. PubMed ID: 27030813
[TBL] [Abstract][Full Text] [Related]
2. The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery.
Rutten IJ; Ubachs J; Kruitwagen RF; van Dijk DP; Beets-Tan RG; Massuger LF; Olde Damink SW; Van Gorp T
Eur J Surg Oncol; 2017 Apr; 43(4):717-724. PubMed ID: 28159443
[TBL] [Abstract][Full Text] [Related]
3. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer.
Rutten IJG; Ubachs J; Kruitwagen RFPM; Beets-Tan RGH; Olde Damink SWM; Van Gorp T
J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):630-638. PubMed ID: 28513088
[TBL] [Abstract][Full Text] [Related]
4. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.
Daly LE; Ní Bhuachalla ÉB; Power DG; Cushen SJ; James K; Ryan AM
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):315-325. PubMed ID: 29318756
[TBL] [Abstract][Full Text] [Related]
5. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
6. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
7. Extreme skeletal muscle loss during induction chemotherapy is an independent predictor of poor survival in advanced epithelial ovarian cancer patients.
Yoshino Y; Taguchi A; Nakajima Y; Takao M; Kashiyama T; Furusawa A; Kino N; Yasugi T
J Obstet Gynaecol Res; 2020 Oct; ():. PubMed ID: 33015913
[TBL] [Abstract][Full Text] [Related]
8. Cachectic Body Composition and Inflammatory Markers Portend a Poor Prognosis in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation.
Naumann P; Eberlein J; Farnia B; Liermann J; Hackert T; Debus J; Combs SE
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717736
[TBL] [Abstract][Full Text] [Related]
9. Computed Tomography-Based Body Composition in Patients With Ovarian Cancer: Association With Chemotoxicity and Prognosis.
Del Grande M; Rizzo S; Nicolino GM; Colombo I; Rossi L; Manganaro L; Del Grande F
Front Oncol; 2021; 11():718815. PubMed ID: 34868915
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.
Degens JHRJ; Sanders KJC; de Jong EEC; Groen HJM; Smit EF; Aerts JG; Schols AMWJ; Dingemans AC
Lung Cancer; 2019 Jul; 133():130-135. PubMed ID: 31200819
[TBL] [Abstract][Full Text] [Related]
11. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer.
Benjamin AJ; Buschmann MM; Zhang SQ; Wroblewski K; Kindler HL; Roggin KK; Dale W
J Geriatr Oncol; 2018 Jul; 9(4):367-372. PubMed ID: 29534880
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience.
Liu Y; Cao L; Chen W; Wang J; Wang W; Liang Z
Medicine (Baltimore); 2020 Sep; 99(36):e22100. PubMed ID: 32899091
[TBL] [Abstract][Full Text] [Related]
13. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
14. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
15. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
16. RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.
Bogani G; Matteucci L; Tamberi S; Ditto A; Sabatucci I; Murgia F; Arcangeli V; Maltese G; Comerci G; Stefanetti M; Sonetto C; Calareso G; Marchiano A; Chiappa V; Lorusso D; Raspagliesi F
Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():93-99. PubMed ID: 31029972
[TBL] [Abstract][Full Text] [Related]
17. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P
Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.
Jung AR; Roh JL; Kim JS; Kim SB; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2019 Jul; 116():98-106. PubMed ID: 31185387
[TBL] [Abstract][Full Text] [Related]
20. Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy.
Chen L; Hao Y; Zhu L; Li S; Zuo Y; Zhang Y; Song H; Xue Y
Onco Targets Ther; 2017; 10():4007-4016. PubMed ID: 28860808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
